Chengdu New Radiomedicine Technology Co., Ltd. (“NRT”), led by veterans in nuclear medicine technology, focuses on the full value chain of medical isotopes production and radiopharmaceutical innovation. The company was founded in 2016 and headquartered in Chengdu, China, home to pandas and a nuclear industrial hub. NRT has four domestic subsidiaries and overseas presence in San Diego, United States and Melbourne, Australia. Our team of 260+ specialists delivers integrated solutions from radiopharmaceutical discovery to global commercialization. NRT has full set of qualifications and licenses, and facilities for medical isotope and radiopharmaceutical R&D, in vivo testing, analysis and GMP compliant production. NRT can provide high quality CDMO and CMO services.

NRT maintains a robust portfolio of medical isotopes produced through accelerator, generator and reactor-based systems. We own the first 30MeV Cyclone® IKON by IBA in Asia, ready by 2025 for production of important therapeutic and imaging isotopes, including Ge-68, Ac-225, Cu-64, I-123, Zr-89, and F-18, etc. Through partnership with Eckert and Ziegler, we've built Yttrium-90 chloride solution production line, with 10,000+ Ci annual yield capacity, and in operation since 2023. With our proprietary technology, NRT has developed Galliator™ Gallium-68 Generator and Techneator™ Technetium-99 Generator. Through collaboration with reactors, we are able to provide Lu-177 chloride solution (n.c.a.) for China market.   

Leveraging rich expertise in nuclear technology and drug innovation, our cross-disciplinary team for radiochemists, clinical researchers and regulatory experts work together to accelerate radioligand (RLT) developments. The iCleave™ Technology, develops purposely-designed linkers for RLT, optimizing bio-distribution, safety and efficacy. NRT proprietary TareSphere™ Ytterium-90 Carbon Microspheres are for cancer treatment using minimally invasive procedures. TareSphere™ are under phase III trial in hepatocellular carcinoma and Phase I/II trial in pancreatic cancer in China. Additionally, the 68Ga NRT6020 and 177Lu-NRT6020 Injections for diagnosis and treatment of FAP positive advanced solid tumors have obtained IND approvals by U.S. FDA.

NRT is committed to becoming a leading enterprise in the field of nuclear medical technology.